Cargando…

P1038: CLINICOPATHOLOGIC AND MOLECULAR CORRELATES OF ORGAN DAMAGE ACROSS THE SPECTRUM OF ADVANCED SYSTEMIC MASTOCYTOSIS

Detalles Bibliográficos
Autores principales:	Liang, E., Perkins, C., Lu, R., Shi, H., Dimitrijevic, S., Hoehn, G., Abuel, J., Langford, C., Abidi, P., Fechter, L., Shomali, W., Gotlib, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430042/ http://dx.doi.org/10.1097/01.HS9.0000847020.88189.e1

Ejemplares similares

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY
por: Reiter, A., et al.
Publicado: (2022)

1038. Rapid Start: A Changing Algorithm for the Management of HIV Infection
por: Gudipati, Smitha, et al.
Publicado: (2020)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022)

P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP
por: Gotlib, Jason, et al.
Publicado: (2023)

P994: HEDGEHOG PATHWAY INVOLVEMENT IN MASTOCYTOSIS DEVELOPMENT
por: Polivka, L., et al.
Publicado: (2022)

The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey
por: Pyatilova, Polina, et al.
Publicado: (2023)

1038. In Vitro Activity of Tebipenem, an Orally Available Carbapenem Agent, Against a Collection of Surveillance Gram-Positive Clinical Isolates
por: Arends, S J Ryan, et al.
Publicado: (2021)

P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL
por: Gotlib, Jason, et al.
Publicado: (2023)

1685-1750 J.S. Bach. Organ Masterpieces. DM-2-1038

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

Adverse reactions to food in patients with mastocytosis
por: Pucino, Valentina, et al.
Publicado: (2011)

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

1038. Edwardsiella tarda Bacteremia: Epidemiology, Clinical Features, and Outcomes
por: Kamiyama, Shinya, et al.
Publicado: (2018)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Association of mastocytosis with interleukin 31 gene polymorphism
por: Nedoszytko, Boguslaw, et al.
Publicado: (2015)

Mastocytosis—A Review of Disease Spectrum with Imaging Correlation
por: Elsaiey, Ahmed, et al.
Publicado: (2021)

1038. Impact of an Electronic Antibiotic Timeout on the Utilization of Frequently Prescribed Antibiotics in Hospitalized Patients
por: Drake, Ty C, et al.
Publicado: (2019)

Hypothetical Protein gene1038 Contributes to Colistin Resistance in Aeromonas hydrophila
por: Liu, Junqi, et al.
Publicado: (2021)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
por: Loschi, Michael, et al.
Publicado: (2023)

P1580: MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS DURING THE COVID-19 PANDEMIC: A SINGLE CENTER EXPERIENCE
por: Filipponi, V., et al.
Publicado: (2022)

Outcomes of 1038 Hip Arthroscopies: A Two-Year Follow-Up Study
por: Lodhia, Parth, et al.
Publicado: (2015)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

The TENDL neutron data library and the TEND1038 38-group neutron constant system
por: Abramovich, S N, et al.
Publicado: (2001)

Environmental and occupational respiratory diseases – 1038. Efficacy of influenza vaccination on pediatric asthma control
por: Fazlollahi, Mohammad Reza, et al.
Publicado: (2013)

1038 Assesing the Management of Urinary Tract Infections at a Large, Urban Teaching Hospital
por: Advani, Shreena, et al.
Publicado: (2014)

Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ(WT/Q1038R) mouse model of autism spectrum disorder
por: Kitagawa, Kohei, et al.
Publicado: (2021)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

P691: MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Publisher Correction: The observation of vibrating pear-shapes in radon nuclei [doi: 10.1038/s41467-019-10494-5]
por: Butler, P A, et al.
Publicado: (2020)

P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME
por: Castells, M., et al.
Publicado: (2022)

Predictors of Clinical Outcomes After Hip Arthroscopy: 5 Year Follow- Up Analysis of 1038 Patients
por: Domb, Benjamin, et al.
Publicado: (2020)

Clinicopathological Profile of Childhood Onset Cutaneous Mastocytosis from a Tertiary Care Center in South India
por: Sathishkumar, Dharshini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c4lja3vk42f56cpcrm0lf145cm